Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Protean Select 2024 Q3 Investor Letter | Buyside Digest

Back to Fund Profile (Protean Select)

Primary Source Intelligence • Q3 2024 Letter Analysis

Protean Select Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Protean Select. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

YTD+12.2%

Annualized+8.6%

Digest Analysis

Quick Take

"Built major position in ITAB following acquisition announcement and accumulated Getinge shares betting regulatory issues are resolving. Added to Novo Nordisk on weakness."

Executive Summary

Protean Select returned 1% in September, bringing YTD performance to 12.2% with volatility below 7%. The fund maintains 28% beta-adjusted net long exposure across a diversified portfolio of Nordic holdings. Key contributors included ITAB Shop Concept, which became the largest position following a major acquisition announcement, and Devyser. Detractors included Novo Nordisk, which saw significant drawdowns despite strong fundamentals, prompting the manager to add to the position. The manager built a significant stake in medtech company Getinge, believing decade-long regulatory issues are finally resolving. A detailed visit to salmon farmer MOWI reinforced conviction in the aquaculture sector, where investment benefits will materialize in 2025. The letter extensively critiques the ESG fund labeling system as ineffective marketing that creates no real impact. Looking forward, the manager sees AI as a structural threat to SaaS companies like Vitec, which trades at 60x FCF despite never addressing AI challenges. Current markets show confusion with fewer fundamental investors, making positioning and flows increasingly important for price movements.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

68%

CautiousHigh

Moderate (68%)

Manager demonstrates moderate-high conviction through concentrated position building in ITAB (largest position), significant accumulation in Getinge, and willingness to add to Novo Nordisk on weakness. Specific company visits and detailed fundamental analysis support conviction, though diversified portfolio structure prevents higher scoring.

Growth Outlook

38%

BearishBullish

Neutral (38%)

The manager describes current markets as 'slightly confusing' with fewer fundamental investors, indicating cautious uncertainty rather than clear optimism or pessimism about market direction.

Risk Appetite

25%

DefensiveAggressive

Defensive (25%)

Portfolio maintains 28% beta-adjusted net long exposure with selective position building in Getinge and adding to Novo Nordisk on weakness, showing moderate risk appetite but not aggressive deployment.

Capital Deployment

20%

De-riskingDeploying

De-risking (20%)

Moderate selective deployment evident through building significant Getinge position, making ITAB the largest holding, and adding to Novo Nordisk during decline. However, also trimmed Boliden, suggesting rotation rather than net deployment.

Forward Guidance

15%

CautiousExpansionary

Cautious (15%)

Manager shows selective deployment bias with specific conviction plays like Getinge and salmon farming, but acknowledges market confusion and maintains cautious positioning overall.

Language Signal

10%

BearishBullish

Bearish (10%)

Language is balanced with both opportunity identification (Getinge resolution, salmon benefits in 2025) and risk awareness (AI threats to SaaS, market confusion), with slight positive tilt.

Perceived Risk

55%

Low RiskElevated

Moderate Risk (55%)

Manager identifies specific structural risks including AI disruption to SaaS models, market confusion from fewer fundamental investors, and rotation pressures. Risks are named and discussed but not characterized as systemic threats.

Opportunity Density

60%

ScarceAbundant

Selective (60%)

Manager sees selective opportunities in specific situations like Getinge's regulatory resolution and salmon farming investment payoffs, but notes market confusion and structural threats to some sectors, indicating moderate opportunity density.

Time Horizon

70%

Short-TermLong-Term

Decade+ (70%)

Manager demonstrates multi-year thinking with salmon farming benefits expected in 2025, Getinge's decade-long regulatory issues finally resolving, and willingness to hold through Novo Nordisk volatility based on long-term fundamentals.